ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD33 Antibody-drug Conjugate BL-M11D1

In Sichuan Biokin Pharmaceutical’s pipeline, CD33 ADC. Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes, led by Sichuan Biokin Pharmaceutical.

Drug pageAnti-CD33 Antibody-drug Conjugate BL-M11D1: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 20, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical43 open or runningphase 3since Nov 20, 2025Jun 16, 2023Dec 2026phase 1 · NCT05924750
  • Named in Sichuan Biokin Pharmaceutical’s own pipeline as BL-M11D1 (CD33 ADC), phase 1, as of Nov 16, 2026 (source).

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2023First study: phase 1 study in RecurrenceFirst studyNCT05924750 · 130 planned · China
  2. Nov 27, 2024Phase 1 study in Leukemia, Myeloid, AcuteNCT06714591 · 52 enrolled · United States
  3. Nov 20, 2025Phase 3 study in Leukemia, Myeloid, AcutePhase 3 reachedNCT07255872 · 216 planned · China
  4. May 9, 2026Phase 2 study in Myelodysplastic SyndromesNCT07591168 · 92 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in RecurrenceNCT05924750
  2. Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07255872
  3. Dec 2028Primary completion: phase 2 study in Myelodysplastic SyndromesNCT07591168

TargetBeta

“CD33 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of gemtuzumab, an immunoglobulin G4 (IgG4) monoclonal antibody directed against the CD33 antigen, ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07591168Myelodysplastic Syndromes · China2Not yet recruitingDec 202892
NCT07255872Leukemia, Myeloid, Acute · China3RecruitingDec 2027216
NCT06714591Leukemia, Myeloid, Acute · United States1TerminatedSep 16, 202652
NCT05924750Recurrence · China1RecruitingDec 2026130

How it is read

Names in the registry

  • “BL-M11D1”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.